Form 4 for MNPR Monopar Therapeutics
Accepted 2024-05-30 00:00:00 ET · period of report 2024-05-28 · accession 0001437749-24-018775 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-05-30 | 2024-05-28 | MNPR | Robinson Chandler | CEO, Dir | X - OptEx | $0.00 | +84.0K | 250.1K | +51% | $0 |
| D | 2024-05-30 | 2024-05-28 | MNPR | Robinson Chandler | CEO, Dir | X - OptEx | $0.00 | -84.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-28 | X | A | 84,000 | $0.00 | 250,130.80 | D | — | — | (F1) This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. |
| 2 | Derivative | Stock Options | 2024-05-28 | X | D | 84,000 | $0.00 | 0 | D | $0.00 · — to 2026-04-03 | 84,000 Common Stock | (F4) Reflects options to purchase up to 84,000 shares of common stock granted to Dr. Robinson on April 4, 2016 for his services as a director and officer of Monopar Therapeutics. The options vested 50% upon grant date, 25% upon the 6-month anniversary of grant date, and 25% upon the 1-year anniversary of grant date. |